The leading European asset manager specializing in digital assets with ~US$10 billion in AuM sets sights on expanding into U.S. market CoinShares ranks among the top four managers globally by crypto ETP AuM alongside BlackRock, Fidelity, and Grayscale and holds the #1 market position in Europe with 34% market share CoinShares is experiencing a period of significant growth; AuM has more than tripled over the last two years through strong investor inflows, supportive digital asset pricing and successful new p ...

Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting SYDNEY, AUSTRALIA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract for the EFTISARC-NEO Phase II investigator-initiated trial has been accepted for oral presentation at the Connectiv ...

On 5 May 2025, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 20 of 2 May 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 120 million during the period 5 May to 31 December 2025. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules). Tr ...

Seasoned industry leader to strengthen company’s strategic engagement and policy voice in Medicare AdvantageORANGE, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today announced that Matt Eyles will join as executive vice president of government and business strategy, effective Sept. 29. In this newly created position, Eyles will report directly to Alignment founder and CEO John Kao, elevating Alignment’s engagement and leadership in health care policy at federal and s ...

Company remains in good standing on Nasdaq Capital Market; strengthens platform to execute commercialization and growth strategyRENO, Nev., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a leader in sustainable lithium battery recycling, today announced that it has received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market and that the m ...

BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational therapy, BA-101, for the treatment of Glioblastoma (GBM). GBM is an aggressive primary brain tumor with limited treatment options and poor prognosis under current standa ...

SINGAPORE, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rectitude Holdings Ltd. (Nasdaq: RECT; the “Company” or “Rectitude”), a Singapore-based provider of safety equipment and related industrial products, today announced that it is initiating a Bitcoin treasury strategy via entering into a Standby Equity Purchase Agreement (the “SEPA”) with Constantinople Limited, a British Virgin Islands Company led by Tian Jia, an experienced Bitcoin investor, as Lead Investor, and Chen Zhiqiang, former co-founder and CTO of Tron, ...

Core Viewpoint - Mohist AI Limited has launched TranGPT, a multilingual AI-powered translation and text-to-speech SaaS platform aimed at enhancing communication for e-commerce sellers, financial professionals, and global enterprises [1][11]. Group 1: Product Features - TranGPT combines neural machine translation with advanced text-to-speech technology, enabling real-time communication across languages, particularly in business-critical scenarios like customer service and financial communication [3][14]. - The platform supports over 30 global languages, including English, Chinese, Japanese, Korean, Turkish, and Thai, allowing users to connect with customers in their native languages [7]. - TranGPT offers real-time AI translation, facilitating instant responses from support teams and financial staff, which leads to faster resolutions and smoother collaboration [8]. - The text-to-speech feature provides natural, human-like voices, enhancing customer experience in call centers and automated support [9]. - The platform operates under Hong Kong jurisdiction, ensuring enterprise-grade security and compliance with data privacy regulations [10]. Group 2: Market Relevance - The growth of cross-border trade, particularly in e-commerce and financial services, highlights the need for effective communication tools, as 70% of buyers are more likely to purchase when addressed in their native language [5]. - TranGPT addresses the language barrier challenge, providing a professional-grade AI tool that ensures accuracy and cultural sensitivity [5]. Group 3: Future Developments - Upcoming enhancements for TranGPT include AI-based voice cloning for personalized communication, multi-channel API integration for seamless workflow, and real-time risk management tools tailored for financial professionals [12][13]. - The company is committed to continuous innovation based on user feedback, aiming to expand TranGPT's capabilities and global reach [11].

SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,099,431 shares of common stock of the Company originally issued in February 2025, having an exercise price of $3.32 per share. The shares of ...

MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received binding commitments for a capital raising of A$20.0 million (the “Placement”) of fully paid ordinary shares (“New Shares”) to International and Australian professional investors. "We are thankful for the continued inte ...